# Osmind **Source:** https://geo.sig.ai/brands/osmind **Vertical:** Healthcare **Subcategory:** General **Tier:** Challenger **Website:** osmind.org **Last Updated:** 2026-04-14 ## Summary SF YC W20 psychiatric EHR for ketamine/psychedelic/TMS treatment practices; $55.2M total ($40M DFJ/General Catalyst/Tiger Series B May 2022) competing with Valant for emerging mental health treatment specialty EHR. ## Company Overview Osmind is a San Francisco-based psychiatry and mental health EHR (electronic health record) platform — backed by Y Combinator (W20) with $55.2 million in total funding including a $40 million Series B in May 2022 led by DFJ Growth with General Catalyst, Future Ventures, Tiger Global, Susa Ventures, Lachy Groom, and Pear VC — providing psychiatric practices with research-grade EHR technology specialized for emerging mental health treatments including ketamine therapy, psychedelic-assisted psychotherapy (psilocybin, MDMA), transcranial magnetic stimulation (TMS), and electroconvulsive therapy (ECT). Founded in 2020, Osmind captures clinical data during novel psychiatric interventions in structured formats that enable both optimized patient care workflows and real-world evidence research — serving the growing segment of psychiatric practices offering treatment-resistant depression interventions. Osmind's specialized psychiatric EHR addresses the workflow and research data gap at the intersection of psychiatry and emerging treatments: general-purpose EHRs (Epic, Athenahealth) capture clinical notes and prescriptions but don't have the structured data fields for ketamine infusion parameters, psychedelic session dosing and set/setting documentation, or TMS treatment course tracking — forcing psychiatrists offering these treatments to use paper forms, Google Docs, or workarounds that neither optimize clinical workflow nor produce the research-quality data that these novel treatments require for outcomes evidence generation. Osmind's platform (purpose-built for the clinical workflow of ketamine and psychedelic-assisted treatment sessions, with structured intake assessments, session documentation forms, and outcome measure tracking using validated psychiatric scales like PHQ-9 and the Mystical Experience Questionnaire) provides both practice efficiency and the clinical database that supports evidence generation. In 2025, Osmind competes in the psychiatric EHR, behavioral health technology, and mental health practice management market with Blueprint (behavioral health EHR, $10M raised), Valant (behavioral health EHR, $45M raised), and Epic (dominant EHR, private, $5B+ revenue) for psychiatric practice and ketamine/psychedelic treatment clinic EHR and practice management platform adoption. DFJ Growth's Series B leadership and General Catalyst's participation reflect healthtech infrastructure conviction. Tiger Global's investment provides growth equity backing for market expansion. Y Combinator W20 connects Osmind with the digital health investment community. The 2025 strategy focuses on growing the ketamine and psychedelic clinic segment (rapidly expanding as treatments gain clinical acceptance), building the real-world evidence database for psychiatric treatment outcomes, and expanding the research network for clinical trials using Osmind's structured data for novel psychiatric treatment investigation. ## Frequently Asked Questions ### What is Osmind? Osmind is the leading psychiatry and mental health EHR platform specializing in emerging treatments including psychedelic medicines, ketamine therapies, and neuromodulation therapies like transcranial magnetic stimulation (TMS). Founded in 2020 and backed by Y Combinator, the company provides research-grade EHR technology that optimizes mental health workflows and patient care journeys. ### What products and services does Osmind offer? Osmind offers a mental health EHR platform with specialized modules for psychedelic therapy, ketamine treatment records, TMS therapy management, and research-grade data capture. The platform is designed to optimize psychiatry workflows and support innovative mental health interventions. ### Who is Osmind designed for? Osmind serves mental health practices and psychiatry providers focused on innovative interventions, including those offering psychedelic medicines, ketamine therapies, and neuromodulation therapies like TMS. The platform is built specifically for providers using emerging mental health treatments. ### When was Osmind founded? Osmind was founded in 2020 and participated in Y Combinator's Winter 2020 (W20) batch. ### Where is Osmind located? Osmind is based in San Francisco, California. ### How much funding has Osmind raised? Osmind has raised $55.2M in total funding, including a $40M Series B round in May 2022 led by DFJ Growth and a $15M Series A in July 2021. Investors include General Catalyst, Future Ventures, Tiger Global, Susa Ventures, Lachy Groom, and Pear VC. ### What makes Osmind unique in the healthcare tech space? Osmind is the first EHR platform specifically designed for psychedelic, ketamine, and TMS therapies. The platform features research-grade data capture capabilities that optimize mental health workflows while serving the emerging field of innovative psychiatric treatments. ### What technology approach does Osmind use? Osmind uses research-grade EHR technology that captures clinical data while optimizing mental health workflows and patient care journeys. The platform is specifically designed to support emerging psychiatric treatments with specialized data capture and management features. ### What are Osmind's key achievements? Osmind has established itself as the leading EHR platform for emerging mental health treatments and successfully raised $55.2M in funding. The company was the first to create an EHR specifically for psychedelic, ketamine, and TMS therapies since its founding in 2020. ### What are Osmind's most recent developments? Osmind raised a $40M Series B round in May 2022 led by DFJ Growth with participation from major investors including Tiger Global and General Catalyst. This followed their $15M Series A round in July 2021. ## Tags healthtech, global, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*